Immunization, Vaccines and Biologicals

SAGE Working Group on pneumococcal polysaccharide vaccines (July 2007 to October 2008)

Terms of Reference

  • Review the evidence with respect to the following 7 questions/issues and to propose to SAGE the related recommendations on vaccine use, maintaining or updating the recommendations stated in the 2003 position paper
    • Review of available data on burden of disease in adults and in high risk groups
    • Effectiveness of PPV23 in elderly population
    • Effectiveness of PPV23 in high risk groups
    • Safety and efficacy of repeated doses of PPV23 in older children and adults
    • Use of PPV23 to boost kids previously immunized with PCV7
    • Impact of giving PPV23 to pregnant women/women of reproductive age in order to prevent pneumo in infants in the first few months of life
    • Consideration of the potential use of PPV23 to mitigate pandemic influenza disease
  • The working group will also identify any additional critical question and will prepare a draft updated position paper on use of PPV23 vaccines.


SAGE Members

  • Art Reingold, Chair
  • Georges Peter


  • Richard Adegbola, Medical Research Council Laboratory, The Gambia
  • Bjarne Bjorvatn, Norway, rapporteur
  • Charles Gilks, WHO, HTM/HIV
  • David Goldblatt, Institute of Child Health, United Kingdom
  • Lisa Jackson, Group Health Center for Health Studies, USA
  • Keith Klugman, Emory University, USA
  • Pekka Nuorti, Centers for Disease Control and Prevention, USA

WHO Secretariat

  • Thomas Cherian
  • Philippe Duclos

Declaration of Interests for WHO Experts

All members completed a declaration of interest. Only three members reported any interest

Dr David Goldblatt
Dr Goldblatt reported that since 2004 he served on the advisory board of the paediatric pneumococcal program at GlaxoSmithKline. He also received small amounts of personal financial compensation for consultanciesand that the Institute of Child Health , UK where he works has received substantial research contracts from 4 companies: Merck & Co Inc; GlaxoSmithKline, Wyeth and Chiron. He acts as principal investigator on these research projects.

Dr Lisa Jackson
Dr Jackson reported having provided some consultancy for Wyeth for which she received a small amount of personal financial compensation and a substantial grant to the research unit to which she belongs at Group health Centre for Health Studies, USA.

Dr Keith Klugman
Dr. Klugman reported his consultancies with three pharmaceutical companies: Merck & Co Inc; GlaxoSmithKline, and Wyeth for which he received a limited personal financial compensation. In addition he reported a Wyeth grant to the Research Unit at Emory University, USA where he works.

Dr Georges Peter
Dr Peter reported serving on the meningococcal Advisory Board for GlaxoSmithKline for which he receives a limited amount of consultancy fees. The last meeting was in 2006. Currently he serves on a Safety Monitoring Board involving post-licensure safety assessment for RotaTeqTM and earlier served on the DSMB for an investigational H5N1 vaccine and for which he has received a small financial compensation from Merck & Co Inc. and Novavax Inc. respectively.

Last updated: 29 January 2009